ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Expert Interviews
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 26793" data-attributes="member: 3"><p>J Urol. 2015 Oct 30. pii: S0022-5347(15)05157-5. doi: 10.1016/j.juro.2015.10.134. [Epub ahead of print]</p><p></p><p>Association between use of exogenous testosterone therapy (eTT) and risk of venous-thrombotic-events among eTT-treated and untreated men with hypogonadism.</p><p></p><p>Li H1, Benoit K2, Wang W2, Motsko S2.</p><p></p><p>Abstract</p><p></p><p>PURPOSE:</p><p></p><p>Limited information exists about whether exogenous testosterone therapy (eTT) is associated with risk of venous thrombotic events (VTE). Here, we investigate via cohort and nested-case-control analyses whether eTT administration is associated with risk of VTE in men with hypogonadism.</p><p></p><p>MATERIALS AND METHODS:</p><p>Databases were reviewed to identify men prescribed eTT and/or men with a hypogonadism diagnosis. Propensity-score 1:1 matching was used to select patients for the cohort analysis. Cases (men with VTE) were matched 1:4 with controls (men without VTE) for the nested-case-control analysis. Primary outcome was defined as incident idiopathic VTE; Cox regression and conditional-logistic regression were used to assess hazard ratios (HRs) and odds ratios (ORs), respectively. Sensitivity analyses were also performed.</p><p></p><p>RESULTS:</p><p>102,650 eTT-treated patients and 102,650 untreated patients were included in the cohort analysis after matching; 2785 cases and 11,119 controls were included in the case-control analysis. Cohort analysis revealed an HR of 1.08 for all eTT-treated patients (95% CI: 0.91, 1.27; p=0.378). Case-control analysis resulted in OR=1.02 (95% CI: 0.92, 1.13; p=0.702) for current eTT exposure and 0.92 (95% CI: 0.82, 1.03; p=0.145) for past eTT exposure. These results remained non statistically significant after stratifying by eTT-administration-route and age category. Results from most of the sensitivity analyses yielded results that were consistent.</p><p></p><p>CONCLUSIONS:</p><p>No significant association was found between eTT and incidents of idiopathic VTE, as well as overall VTE in men with hypogonadism; however, some discrepant findings exist for the association between injectable formulations and overall VTE risk.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 26793, member: 3"] J Urol. 2015 Oct 30. pii: S0022-5347(15)05157-5. doi: 10.1016/j.juro.2015.10.134. [Epub ahead of print] Association between use of exogenous testosterone therapy (eTT) and risk of venous-thrombotic-events among eTT-treated and untreated men with hypogonadism. Li H1, Benoit K2, Wang W2, Motsko S2. Abstract PURPOSE: Limited information exists about whether exogenous testosterone therapy (eTT) is associated with risk of venous thrombotic events (VTE). Here, we investigate via cohort and nested-case-control analyses whether eTT administration is associated with risk of VTE in men with hypogonadism. MATERIALS AND METHODS: Databases were reviewed to identify men prescribed eTT and/or men with a hypogonadism diagnosis. Propensity-score 1:1 matching was used to select patients for the cohort analysis. Cases (men with VTE) were matched 1:4 with controls (men without VTE) for the nested-case-control analysis. Primary outcome was defined as incident idiopathic VTE; Cox regression and conditional-logistic regression were used to assess hazard ratios (HRs) and odds ratios (ORs), respectively. Sensitivity analyses were also performed. RESULTS: 102,650 eTT-treated patients and 102,650 untreated patients were included in the cohort analysis after matching; 2785 cases and 11,119 controls were included in the case-control analysis. Cohort analysis revealed an HR of 1.08 for all eTT-treated patients (95% CI: 0.91, 1.27; p=0.378). Case-control analysis resulted in OR=1.02 (95% CI: 0.92, 1.13; p=0.702) for current eTT exposure and 0.92 (95% CI: 0.82, 1.03; p=0.145) for past eTT exposure. These results remained non statistically significant after stratifying by eTT-administration-route and age category. Results from most of the sensitivity analyses yielded results that were consistent. CONCLUSIONS: No significant association was found between eTT and incidents of idiopathic VTE, as well as overall VTE in men with hypogonadism; however, some discrepant findings exist for the association between injectable formulations and overall VTE risk. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Expert Interviews
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top